The scarcity of consolidated and accessible summaries of research on the impact of various drugs and compounds targeting GSK-3β within the PI3K/Akt pathway, specifically in the context of liver cancer, has posed challenges in information retrieval and synthesis. Here, AKT1 is linked to liver cancer.